<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37076602</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-1784</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature reviews. Drug discovery</Title><ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation></Journal><ArticleTitle>Therapeutic strategies for COVID-19: progress and lessons learned.</ArticleTitle><Pagination><StartPage>449</StartPage><EndPage>475</EndPage><MedlinePgn>449-475</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41573-023-00672-y</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous efforts to develop therapeutic strategies that target severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and/or human proteins to control viral infection, encompassing hundreds of potential drugs and thousands of patients in clinical trials. So far, a few small-molecule antiviral drugs (nirmatrelvir-ritonavir, remdesivir and molnupiravir) and 11 monoclonal antibodies have been marketed for the treatment of COVID-19, mostly requiring administration within 10 days of symptom onset. In addition, hospitalized patients with severe or critical COVID-19 may benefit from treatment with previously approved immunomodulatory drugs, including glucocorticoids such as dexamethasone, cytokine antagonists such as tocilizumab and Janus kinase inhibitors such as baricitinib. Here, we summarize progress with COVID-19 drug discovery, based on accumulated findings since the pandemic began and a comprehensive list of clinical and preclinical inhibitors with anti-coronavirus activities. We also discuss the lessons learned from COVID-19 and other infectious diseases with regard to drug repurposing strategies, pan-coronavirus drug targets, in vitro assays and animal models, and platform trial design for the development of therapeutics to tackle COVID-19, long COVID and pathogenic coronaviruses in future outbreaks.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Guangdi</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8852-034X</Identifier><AffiliationInfo><Affiliation>Xiangya School of Public Health, Central South University; Hunan Children's Hospital, Changsha, China. liguangdi.research@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilgenfeld</LastName><ForeName>Rolf</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-8850-2977</Identifier><AffiliationInfo><Affiliation>Institute of Molecular Medicine &amp; German Center for Infection Research (DZIF), University of L&#xfc;beck, L&#xfc;beck, Germany. rolf.hilgenfeld@uni-luebeck.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whitley</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9959-9276</Identifier><AffiliationInfo><Affiliation>Department of Paediatrics, Microbiology, Medicine and Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA. rwhitley@uabmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Clercq</LastName><ForeName>Erik</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2985-8890</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. erik.declercq@kuleuven.be.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Drug Discov</MedlineTA><NlmUniqueID>101124171</NlmUniqueID><ISSNLinking>1474-1776</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>R.H. filed a patent application covering &#x3b1;-ketoamide M<sup>pro</sup> inhibitors of the 13b family. He discloses a research collaboration with Atea Pharmaceuticals. Other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>20</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37076602</ArticleId><ArticleId IdType="pmc">PMC10113999</ArticleId><ArticleId IdType="doi">10.1038/s41573-023-00672-y</ArticleId><ArticleId IdType="pii">10.1038/s41573-023-00672-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holmes EC, et al. The origins of SARS-CoV-2: a critical review. Cell. 2021;184:4848&#x2013;4856. doi: 10.1016/j.cell.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC8373617</ArticleId><ArticleId IdType="pubmed">34480864</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N, et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727&#x2013;733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. Pan-coronavirus vaccine pipeline takes form. Nat. Rev. Drug Discov. 2022;21:324&#x2013;326. doi: 10.1038/d41573-022-00074-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-022-00074-6</ArticleId><ArticleId IdType="pubmed">35440811</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary N, Weissman D, Whitehead KA. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 2021;20:817&#x2013;838. doi: 10.1038/s41573-021-00283-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00283-5</ArticleId><ArticleId IdType="pmc">PMC8386155</ArticleId><ArticleId IdType="pubmed">34433919</ArticleId></ArticleIdList></Reference><Reference><Citation>De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 2016;29:695&#x2013;747. doi: 10.1128/CMR.00102-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00102-15</ArticleId><ArticleId IdType="pmc">PMC4978613</ArticleId><ArticleId IdType="pubmed">27281742</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, G. &amp; De Clercq, E. in Antiviral Discovery for Highly Pathogenic Emerging Viruses (eds Mu&#xf1;oz-Fontela, C. &amp; Delgado, R.) 1&#x2013;27 (Royal Society of Chemistry, 2022).</Citation></Reference><Reference><Citation>Li, G., Jing, X., Zhang, P. &amp; De Clercq, E. in Encyclopedia of Virology (Fourth Edition) (eds Bamford, D. &amp; Zuckerman, M.) Ch. 1, 121&#x2013;130 (Academic Press, 2021).</Citation></Reference><Reference><Citation>Meganck RM, Baric RS. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat. Med. 2021;27:401&#x2013;410. doi: 10.1038/s41591-021-01282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01282-0</ArticleId><ArticleId IdType="pubmed">33723456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat. Rev. Drug Discov. 2018;17:35&#x2013;56. doi: 10.1038/nrd.2017.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.162</ArticleId><ArticleId IdType="pmc">PMC7097079</ArticleId><ArticleId IdType="pubmed">28935918</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J, Vanstreels E, Jansen S, Daelemans D. Cellular host factors for SARS-CoV-2 infection. Nat. Microbiol. 2021;6:1219&#x2013;1232. doi: 10.1038/s41564-021-00958-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00958-0</ArticleId><ArticleId IdType="pubmed">34471255</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu SX, et al. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 2021;18:194&#x2013;209. doi: 10.1038/s41569-020-00469-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-00469-1</ArticleId><ArticleId IdType="pmc">PMC7675396</ArticleId><ArticleId IdType="pubmed">33214651</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantaleo G, Correia B, Fenwick C, Joo VS, Perez L. Antibodies to combat viral infections: development strategies and progress. Nat. Rev. Drug Discov. 2022;21:676&#x2013;696. doi: 10.1038/s41573-022-00495-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00495-3</ArticleId><ArticleId IdType="pmc">PMC9207876</ArticleId><ArticleId IdType="pubmed">35725925</ArticleId></ArticleIdList></Reference><Reference><Citation>Boike L, Henning NJ, Nomura DK. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 2022;21:881&#x2013;898. doi: 10.1038/s41573-022-00542-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00542-z</ArticleId><ArticleId IdType="pmc">PMC9403961</ArticleId><ArticleId IdType="pubmed">36008483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H, et al. Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron variant. Clin. Microbiol. Rev. 2022;35:e0001422. doi: 10.1128/cmr.00014-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cmr.00014-22</ArticleId><ArticleId IdType="pmc">PMC9491202</ArticleId><ArticleId IdType="pubmed">35862736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao K, et al. SARS-CoV-2 antiviral therapy. Clin. Microbiol. Rev. 2021;34:e0010921. doi: 10.1128/CMR.00109-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00109-21</ArticleId><ArticleId IdType="pmc">PMC8404831</ArticleId><ArticleId IdType="pubmed">34319150</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 2023;23:189&#x2013;199. doi: 10.1038/s41577-022-00784-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00784-3</ArticleId><ArticleId IdType="pmc">PMC9514166</ArticleId><ArticleId IdType="pubmed">36168054</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 2021;21:626&#x2013;636. doi: 10.1038/s41577-021-00592-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00592-1</ArticleId><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Drain PK. Rapid diagnostic testing for SARS-CoV-2. N. Engl. J. Med. 2022;386:264&#x2013;272. doi: 10.1056/NEJMcp2117115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2117115</ArticleId><ArticleId IdType="pmc">PMC8820190</ArticleId><ArticleId IdType="pubmed">34995029</ArticleId></ArticleIdList></Reference><Reference><Citation>Peeling RW, Heymann DL, Teo YY, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399:757&#x2013;768. doi: 10.1016/S0140-6736(21)02346-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02346-1</ArticleId><ArticleId IdType="pmc">PMC8687671</ArticleId><ArticleId IdType="pubmed">34942102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat. Rev. Microbiol. 2022;20:270&#x2013;284. doi: 10.1038/s41579-022-00713-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00713-0</ArticleId><ArticleId IdType="pubmed">35354968</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155&#x2013;170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020;26:1017&#x2013;1032. doi: 10.1038/s41591-020-0968-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. Nat. Immunol. 2022;23:165&#x2013;176. doi: 10.1038/s41590-021-01091-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01091-0</ArticleId><ArticleId IdType="pmc">PMC8935980</ArticleId><ArticleId IdType="pubmed">35105981</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkoff JM, tenOever B. Innate immune evasion strategies of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:178&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9838430</ArticleId><ArticleId IdType="pubmed">36631691</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 2021;19:685&#x2013;700. doi: 10.1038/s41579-021-00630-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00630-8</ArticleId><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B, Urakova N, Snijder EJ, Campbell EA. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 2022;23:21&#x2013;39. doi: 10.1038/s41580-021-00432-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00432-z</ArticleId><ArticleId IdType="pmc">PMC8613731</ArticleId><ArticleId IdType="pubmed">34824452</ArticleId></ArticleIdList></Reference><Reference><Citation>DeGrace MM, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022;605:640&#x2013;652. doi: 10.1038/s41586-022-04690-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04690-5</ArticleId><ArticleId IdType="pmc">PMC9345323</ArticleId><ArticleId IdType="pubmed">35361968</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Lai S, Gao GF, Shi W. The emergence, genomic diversity and global spread of SARS-CoV-2. Nature. 2021;600:408&#x2013;418. doi: 10.1038/s41586-021-04188-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04188-6</ArticleId><ArticleId IdType="pubmed">34880490</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses &#x2014; drug discovery and therapeutic options. Nat. Rev. Drug. Discov. 2016;15:327&#x2013;347. doi: 10.1038/nrd.2015.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2015.37</ArticleId><ArticleId IdType="pmc">PMC7097181</ArticleId><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Su S, Yang H, Jiang S. Antivirals with common targets against highly pathogenic viruses. Cell. 2021;184:1604&#x2013;1620. doi: 10.1016/j.cell.2021.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.013</ArticleId><ArticleId IdType="pubmed">33740455</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P, et al. Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host Microbe. 2020;28:586&#x2013;601.e586. doi: 10.1016/j.chom.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7443692</ArticleId><ArticleId IdType="pubmed">32841605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp D, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260&#x2013;1263. doi: 10.1126/science.abb2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2507</ArticleId><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou T, et al. Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains. Cell Host Microbe. 2020;28:867&#x2013;879.e865. doi: 10.1016/j.chom.2020.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7670890</ArticleId><ArticleId IdType="pubmed">33271067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. FDA approves 100th monoclonal antibody product. Nat. Rev. Drug Discov. 2021;20:491&#x2013;495. doi: 10.1038/d41573-021-00079-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-021-00079-7</ArticleId><ArticleId IdType="pubmed">33953368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhimraj A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis. 2022 doi: 10.1093/cid/ciac724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac724</ArticleId><ArticleId IdType="pmc">PMC7197612</ArticleId><ArticleId IdType="pubmed">32338708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M, et al. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat. Rev. Microbiol. 2023;21:112&#x2013;124. doi: 10.1038/s41579-022-00809-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00809-7</ArticleId><ArticleId IdType="pmc">PMC9616429</ArticleId><ArticleId IdType="pubmed">36307535</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 2019;10:1296. doi: 10.3389/fimmu.2019.01296.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01296</ArticleId><ArticleId IdType="pmc">PMC6568213</ArticleId><ArticleId IdType="pubmed">31231397</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo YM, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Sci. Transl. Med. 2022;14:eabl8124. doi: 10.1126/scitranslmed.abl8124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abl8124</ArticleId><ArticleId IdType="pmc">PMC8939769</ArticleId><ArticleId IdType="pubmed">35076282</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, et al. COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes. Clin. Microbiol. Rev. 2022;35:e0020021. doi: 10.1128/cmr.00200-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cmr.00200-21</ArticleId><ArticleId IdType="pmc">PMC9491201</ArticleId><ArticleId IdType="pubmed">35262370</ArticleId></ArticleIdList></Reference><Reference><Citation>Senefeld JW, Casadevall A, Joyner MJ. Convalescent plasma to deliver therapeutic antibodies against COVID-19. Trends Mol. Med. 2022;28:435&#x2013;436. doi: 10.1016/j.molmed.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8858694</ArticleId><ArticleId IdType="pubmed">35248476</ArticleId></ArticleIdList></Reference><Reference><Citation>Troxel AB, et al. Association of convalescent plasma treatment with clinical status in patients hospitalized with COVID-19: a meta-analysis. JAMA Netw. Open. 2022;5:e2147331. doi: 10.1001/jamanetworkopen.2021.47331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.47331</ArticleId><ArticleId IdType="pmc">PMC8790669</ArticleId><ArticleId IdType="pubmed">35076699</ArticleId></ArticleIdList></Reference><Reference><Citation>Millat-Martinez P, et al. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nat. Commun. 2022;13:2583. doi: 10.1038/s41467-022-29911-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29911-3</ArticleId><ArticleId IdType="pmc">PMC9095637</ArticleId><ArticleId IdType="pubmed">35546145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat. Microbiol. 2020;5:1185&#x2013;1191. doi: 10.1038/s41564-020-00789-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-00789-5</ArticleId><ArticleId IdType="pubmed">32908214</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CO, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588:682&#x2013;687. doi: 10.1038/s41586-020-2852-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2852-1</ArticleId><ArticleId IdType="pmc">PMC8092461</ArticleId><ArticleId IdType="pubmed">33045718</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183:1024&#x2013;1042.e1021. doi: 10.1016/j.cell.2020.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 2021;21:382&#x2013;393. doi: 10.1038/s41577-021-00542-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00542-x</ArticleId><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature. 2022;602:676&#x2013;681. doi: 10.1038/s41586-021-04388-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04388-0</ArticleId><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657&#x2013;663. doi: 10.1038/s41586-021-04385-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Recovery Collaborative Group. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022;399:665&#x2013;676. doi: 10.1016/S0140-6736(22)00163-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00163-5</ArticleId><ArticleId IdType="pmc">PMC8830904</ArticleId><ArticleId IdType="pubmed">35151397</ArticleId></ArticleIdList></Reference><Reference><Citation>Activ-Tico Bamlanivimab Study Group. Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial. Ann. Intern. Med. 2021;175:234&#x2013;243. doi: 10.7326/M21-3507.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-3507</ArticleId><ArticleId IdType="pmc">PMC9334931</ArticleId><ArticleId IdType="pubmed">34928698</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker LM, Burton DR. Passive immunotherapy of viral infections: &#x2018;super-antibodies&#x2019; enter the fray. Nat. Rev. Immunol. 2018;18:297&#x2013;308. doi: 10.1038/nri.2017.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.148</ArticleId><ArticleId IdType="pmc">PMC5918154</ArticleId><ArticleId IdType="pubmed">29379211</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng YQ, et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 2022;32:375&#x2013;382. doi: 10.1038/s41422-022-00630-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00630-0</ArticleId><ArticleId IdType="pmc">PMC8866932</ArticleId><ArticleId IdType="pubmed">35210606</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol. Immunol. 2020;17:765&#x2013;767. doi: 10.1038/s41423-020-0374-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0374-2</ArticleId><ArticleId IdType="pmc">PMC7075278</ArticleId><ArticleId IdType="pubmed">32047258</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363:938&#x2013;947. doi: 10.1016/S0140-6736(04)15788-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)15788-7</ArticleId><ArticleId IdType="pmc">PMC7140173</ArticleId><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 2014;5:3067. doi: 10.1038/ncomms4067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4067</ArticleId><ArticleId IdType="pmc">PMC7091805</ArticleId><ArticleId IdType="pubmed">24473083</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature. 1993;365:113. doi: 10.1038/365113a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/365113a0</ArticleId><ArticleId IdType="pubmed">8371754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan Q, et al. Pan-coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus infectious diseases. J. Med. Virol. 2023;95:e28143. doi: 10.1002/jmv.28143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28143</ArticleId><ArticleId IdType="pmc">PMC9539121</ArticleId><ArticleId IdType="pubmed">36098460</ArticleId></ArticleIdList></Reference><Reference><Citation>Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat. Rev. Drug Discov. 2021;20:309&#x2013;325. doi: 10.1038/s41573-020-00135-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-00135-8</ArticleId><ArticleId IdType="pubmed">33536635</ArticleId></ArticleIdList></Reference><Reference><Citation>Davenport AP, Scully CCG, de Graaf C, Brown AJH, Maguire JJ. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat. Rev. Drug Discov. 2020;19:389&#x2013;413. doi: 10.1038/s41573-020-0062-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0062-z</ArticleId><ArticleId IdType="pubmed">32494050</ArticleId></ArticleIdList></Reference><Reference><Citation>ACTIV-3/TICO Study Group. Efficacy and safety of ensovibep for adults hospitalized with COVID-19: a randomized controlled trial. Ann. Intern. Med. 2022;175:1266&#x2013;1274. doi: 10.7326/M22-1503.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-1503</ArticleId><ArticleId IdType="pmc">PMC9384272</ArticleId><ArticleId IdType="pubmed">35939810</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657&#x2013;662. doi: 10.1038/s41586-020-2601-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2601-5</ArticleId><ArticleId IdType="pmc">PMC7116779</ArticleId><ArticleId IdType="pubmed">32726803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rut W, et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design. Sci. Adv. 2020;6:eabd4596. doi: 10.1126/sciadv.abd4596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd4596</ArticleId><ArticleId IdType="pmc">PMC7567588</ArticleId><ArticleId IdType="pubmed">33067239</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z, et al. Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J. Med. Chem. 2022;65:2940&#x2013;2955. doi: 10.1021/acs.jmedchem.1c01307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01307</ArticleId><ArticleId IdType="pmc">PMC8547495</ArticleId><ArticleId IdType="pubmed">34665619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, et al. Targeting papain-like protease for broad-spectrum coronavirus inhibition. Protein Cell. 2022;13:940&#x2013;953. doi: 10.1007/s13238-022-00909-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-022-00909-3</ArticleId><ArticleId IdType="pmc">PMC8983325</ArticleId><ArticleId IdType="pubmed">35384604</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargsyan K, et al. Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors. Chem. Sci. 2020;11:9904&#x2013;9909. doi: 10.1039/D0SC02646H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0SC02646H</ArticleId><ArticleId IdType="pmc">PMC8162115</ArticleId><ArticleId IdType="pubmed">34094251</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan H, Hu Y, Jadhav P, Tan B, Wang J. Progress and challenges in targeting the SARS-CoV-2 papain-like protease. J. Med. Chem. 2022;65:7561&#x2013;7580. doi: 10.1021/acs.jmedchem.2c00303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00303</ArticleId><ArticleId IdType="pmc">PMC9159073</ArticleId><ArticleId IdType="pubmed">35620927</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratia K, et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl Acad. Sci. USA. 2006;103:5717&#x2013;5722. doi: 10.1073/pnas.0510851103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0510851103</ArticleId><ArticleId IdType="pmc">PMC1458639</ArticleId><ArticleId IdType="pubmed">16581910</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat. Rev. Drug Discov. 2018;17:57&#x2013;78. doi: 10.1038/nrd.2017.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2017.152</ArticleId><ArticleId IdType="pmc">PMC7097658</ArticleId><ArticleId IdType="pubmed">28959952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao K, et al. Perspectives on SARS-CoV-2 main protease inhibitors. J. Med. Chem. 2021;64:16922&#x2013;16955. doi: 10.1021/acs.jmedchem.1c00409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00409</ArticleId><ArticleId IdType="pmc">PMC9357291</ArticleId><ArticleId IdType="pubmed">34798775</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidak E, Javorsek U, Vizovisek M, Turk B. Cysteine cathepsins and their extracellular roles: shaping the microenvironment. Cells. 2019;8:264. doi: 10.3390/cells8030264.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8030264</ArticleId><ArticleId IdType="pmc">PMC6468544</ArticleId><ArticleId IdType="pubmed">30897858</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020;368:409&#x2013;412. doi: 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper MS, et al. Diastereomeric resolution yields highly potent inhibitor of SARS-CoV-2 main protease. J. Med. Chem. 2022;65:13328&#x2013;13342. doi: 10.1021/acs.jmedchem.2c01131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c01131</ArticleId><ArticleId IdType="pmc">PMC9574927</ArticleId><ArticleId IdType="pubmed">36179320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289&#x2013;293. doi: 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh AK, Osswald HL, Prato G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med. Chem. 2016;59:5172&#x2013;5208. doi: 10.1021/acs.jmedchem.5b01697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.5b01697</ArticleId><ArticleId IdType="pmc">PMC5598487</ArticleId><ArticleId IdType="pubmed">26799988</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell. 2022;13:689&#x2013;693. doi: 10.1007/s13238-021-00883-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-021-00883-2</ArticleId><ArticleId IdType="pmc">PMC8533666</ArticleId><ArticleId IdType="pubmed">34687004</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen DR, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586&#x2013;1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Greasley SE, et al. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J. Biol. Chem. 2022;298:101972. doi: 10.1016/j.jbc.2022.101972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.101972</ArticleId><ArticleId IdType="pmc">PMC9023115</ArticleId><ArticleId IdType="pubmed">35461811</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 2022;607:119&#x2013;127. doi: 10.1038/s41586-022-04856-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04856-1</ArticleId><ArticleId IdType="pmc">PMC10579982</ArticleId><ArticleId IdType="pubmed">35576972</ArticleId></ArticleIdList></Reference><Reference><Citation>Malla TR, et al. Penicillin derivatives inhibit the SARS-CoV-2 main protease by reaction with its nucleophilic cysteine. J. Med. Chem. 2022;65:7682&#x2013;7696. doi: 10.1021/acs.jmedchem.1c02214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c02214</ArticleId><ArticleId IdType="pmc">PMC9115881</ArticleId><ArticleId IdType="pubmed">35549342</ArticleId></ArticleIdList></Reference><Reference><Citation>Amporndanai K, et al. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat. Commun. 2021;12:3061. doi: 10.1038/s41467-021-23313-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23313-7</ArticleId><ArticleId IdType="pmc">PMC8144557</ArticleId><ArticleId IdType="pubmed">34031399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh AK, et al. Indole chloropyridinyl ester-derived SARS-CoV-2 3 CLpro inhibitors: enzyme inhibition, antiviral efficacy, structure-activity relationship, and X-ray structural studies. J. Med. Chem. 2021;64:14702&#x2013;14714. doi: 10.1021/acs.jmedchem.1c01214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01214</ArticleId><ArticleId IdType="pmc">PMC8457330</ArticleId><ArticleId IdType="pubmed">34528437</ArticleId></ArticleIdList></Reference><Reference><Citation>Dampalla CS, et al. Structure-guided design of potent spirocyclic inhibitors of severe acute respiratory syndrome coronavirus-2 3C-like protease. J. Med. Chem. 2022;65:7818&#x2013;7832. doi: 10.1021/acs.jmedchem.2c00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00224</ArticleId><ArticleId IdType="pmc">PMC9172056</ArticleId><ArticleId IdType="pubmed">35638577</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H, et al. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat. Commun. 2021;12:3623. doi: 10.1038/s41467-021-23751-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23751-3</ArticleId><ArticleId IdType="pmc">PMC8206078</ArticleId><ArticleId IdType="pubmed">34131140</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoh Y, et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 2022;65:6499&#x2013;6512. doi: 10.1021/acs.jmedchem.2c00117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00117</ArticleId><ArticleId IdType="pmc">PMC8982737</ArticleId><ArticleId IdType="pubmed">35352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H, et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study. Clin. Infect. Dis. 2022 doi: 10.1093/cid/ciac933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac933</ArticleId><ArticleId IdType="pmc">PMC10110269</ArticleId><ArticleId IdType="pubmed">36477182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman RL, et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. J. Med. Chem. 2020;63:12725&#x2013;12747. doi: 10.1021/acs.jmedchem.0c01063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01063</ArticleId><ArticleId IdType="pmc">PMC7571312</ArticleId><ArticleId IdType="pubmed">33054210</ArticleId></ArticleIdList></Reference><Reference><Citation>Rut W, et al. SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. 2021;17:222&#x2013;228. doi: 10.1038/s41589-020-00689-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41589-020-00689-z</ArticleId><ArticleId IdType="pubmed">33093684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AS, Caubel P, Rusnak JM, EPIC-HR Investigators. Nirmatrelvir-ritonavir and viral load rebound in Covid-19. N. Engl. J. Med. 2022;387:1047&#x2013;1049. doi: 10.1056/NEJMc2205944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2205944</ArticleId><ArticleId IdType="pmc">PMC9513855</ArticleId><ArticleId IdType="pubmed">36069818</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;613:558&#x2013;564. doi: 10.1038/s41586-022-05514-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05514-2</ArticleId><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou Z, Rao Z. The life of SARS-CoV-2 inside cells: replication-transcription complex assembly and function. Annu. Rev. Biochem. 2022;91:381&#x2013;401. doi: 10.1146/annurev-biochem-052521-115653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-052521-115653</ArticleId><ArticleId IdType="pubmed">35729072</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L, et al. Cryo-EM structure of an extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in cap synthesis. Cell. 2021;184:184&#x2013;193.e110. doi: 10.1016/j.cell.2020.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.11.016</ArticleId><ArticleId IdType="pmc">PMC7666536</ArticleId><ArticleId IdType="pubmed">33232691</ArticleId></ArticleIdList></Reference><Reference><Citation>Slanina H, et al. Coronavirus replication-transcription complex: vital and selective NMPylation of a conserved site in nsp9 by the NiRAN-RdRp subunit. Proc. Natl Acad. Sci. USA. 2021;118:e2022310118. doi: 10.1073/pnas.2022310118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2022310118</ArticleId><ArticleId IdType="pmc">PMC8017715</ArticleId><ArticleId IdType="pubmed">33472860</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AP, et al. The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme. Nucleic Acids Res. 2021;49:13019&#x2013;13030. doi: 10.1093/nar/gkab1160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1160</ArticleId><ArticleId IdType="pmc">PMC8682786</ArticleId><ArticleId IdType="pubmed">34850141</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon A, et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat. Commun. 2022;13:621. doi: 10.1038/s41467-022-28113-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28113-1</ArticleId><ArticleId IdType="pmc">PMC8810794</ArticleId><ArticleId IdType="pubmed">35110538</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedy A, et al. Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2. PLoS Comput. Biol. 2021;17:e1009384. doi: 10.1371/journal.pcbi.1009384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009384</ArticleId><ArticleId IdType="pmc">PMC8478224</ArticleId><ArticleId IdType="pubmed">34516563</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Wang Y, De Clercq E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm. Sin. B. 2022;14:1567&#x2013;1590. doi: 10.1016/j.apsb.2021.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.11.009</ArticleId><ArticleId IdType="pmc">PMC9279714</ArticleId><ArticleId IdType="pubmed">35847492</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihlar T, Mackman RL. Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir. Ther. 2022;27:13596535221082773. doi: 10.1177/13596535221082773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13596535221082773</ArticleId><ArticleId IdType="pubmed">35499114</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho A, et al. Synthesis and antiviral activity of a series of 1&#x2019;-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 2012;22:2705&#x2013;2707. doi: 10.1016/j.bmcl.2012.02.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2012.02.105</ArticleId><ArticleId IdType="pmc">PMC7126871</ArticleId><ArticleId IdType="pubmed">22446091</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel D, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J. Med. Chem. 2017;60:1648&#x2013;1661. doi: 10.1021/acs.jmedchem.6b01594.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01594</ArticleId><ArticleId IdType="pubmed">28124907</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleissa MM, et al. New perspectives on antimicrobial agents: remdesivir treatment for COVID-19. Antimicrob. Agents Chemother. 2020;65:e01814&#x2013;e01820. doi: 10.1128/AAC.01814-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01814-20</ArticleId><ArticleId IdType="pmc">PMC7927874</ArticleId><ArticleId IdType="pubmed">33139290</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulangu S, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N. Engl. J. Med. 2019;381:2293&#x2013;2303. doi: 10.1056/NEJMoa1910993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1910993</ArticleId><ArticleId IdType="pmc">PMC10680050</ArticleId><ArticleId IdType="pubmed">31774950</ArticleId></ArticleIdList></Reference><Reference><Citation>Malin JJ, Suarez I, Priesner V, Fatkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin. Microbiol. Rev. 2020;34:e00162-20. doi: 10.1128/CMR.00162-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00162-20</ArticleId><ArticleId IdType="pmc">PMC7566896</ArticleId><ArticleId IdType="pubmed">33055231</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon CJ, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J. Biol. Chem. 2020;295:6785&#x2013;6797. doi: 10.1074/jbc.RA120.013679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.013679</ArticleId><ArticleId IdType="pmc">PMC7242698</ArticleId><ArticleId IdType="pubmed">32284326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokic G, et al. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat. Commun. 2021;12:279. doi: 10.1038/s41467-020-20542-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20542-0</ArticleId><ArticleId IdType="pmc">PMC7804290</ArticleId><ArticleId IdType="pubmed">33436624</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941&#x2013;1953. doi: 10.1016/S0140-6736(22)00519-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00519-0</ArticleId><ArticleId IdType="pmc">PMC9060606</ArticleId><ArticleId IdType="pubmed">35512728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ader F, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 2022;22:209&#x2013;221. doi: 10.1016/S1473-3099(21)00485-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00485-0</ArticleId><ArticleId IdType="pmc">PMC8439621</ArticleId><ArticleId IdType="pubmed">34534511</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaseem A, et al. Should remdesivir be used for the treatment of patients with COVID-19? Rapid, living practice points from the American College of Physicians (Version 2) Ann. Intern. Med. 2021;174:673&#x2013;679. doi: 10.7326/M20-8101.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-8101</ArticleId><ArticleId IdType="pmc">PMC7983309</ArticleId><ArticleId IdType="pubmed">33560862</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Wang Z. Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment. Acta Pharm. Sin. B. 2021;11:1607&#x2013;1616. doi: 10.1016/j.apsb.2021.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC8245906</ArticleId><ArticleId IdType="pubmed">34221871</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z, et al. VV116 versus nirmatrelvir&#x2013;ritonavir for oral treatment of Covid-19. N. Engl. J. Med. 2023;388:406&#x2013;417. doi: 10.1056/NEJMoa2208822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208822</ArticleId><ArticleId IdType="pmc">PMC9812289</ArticleId><ArticleId IdType="pubmed">36577095</ArticleId></ArticleIdList></Reference><Reference><Citation>Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId><ArticleId IdType="pmc">PMC6848974</ArticleId><ArticleId IdType="pubmed">31645453</ArticleId></ArticleIdList></Reference><Reference><Citation>Janion C, Glickman BW. N4-hydroxycytidine: a mutagen specific for AT to GC transitions. Mutat. Res. 1980;72:43&#x2013;47. doi: 10.1016/0027-5107(80)90218-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0027-5107(80)90218-3</ArticleId><ArticleId IdType="pubmed">6160396</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12:eabb5883. doi: 10.1126/scitranslmed.abb5883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId><ArticleId IdType="pmc">PMC7164393</ArticleId><ArticleId IdType="pubmed">32253226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl A, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451&#x2013;457. doi: 10.1038/s41586-021-03312-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId><ArticleId IdType="pmc">PMC7979515</ArticleId><ArticleId IdType="pubmed">33561864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 2022;386:509&#x2013;520. doi: 10.1056/NEJMoa2116044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116044</ArticleId><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler CC, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401:281&#x2013;293. doi: 10.1016/S0140-6736(22)02597-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02597-1</ArticleId><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip TCF, et al. Impact of the use of oral antiviral agents on the risk of hospitalization in community COVID-19 patients. Clin. Infect. Dis. 2023;76:e26&#x2013;e33. doi: 10.1093/cid/ciac687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac687</ArticleId><ArticleId IdType="pmc">PMC9452147</ArticleId><ArticleId IdType="pubmed">36031408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabinger F, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021;28:740&#x2013;746. doi: 10.1038/s41594-021-00651-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-021-00651-0</ArticleId><ArticleId IdType="pmc">PMC8437801</ArticleId><ArticleId IdType="pubmed">34381216</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanstrom R, Schinazi RF. Lethal mutagenesis as an antiviral strategy. Science. 2022;375:497&#x2013;498. doi: 10.1126/science.abn0048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn0048</ArticleId><ArticleId IdType="pubmed">35113690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon CJ, Tchesnokov EP, Schinazi RF, Gotte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021;297:100770. doi: 10.1016/j.jbc.2021.100770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100770</ArticleId><ArticleId IdType="pmc">PMC8110631</ArticleId><ArticleId IdType="pubmed">33989635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, et al. &#x3b2;-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 2021;224:415&#x2013;419. doi: 10.1093/infdis/jiab247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab247</ArticleId><ArticleId IdType="pmc">PMC8136050</ArticleId><ArticleId IdType="pubmed">33961695</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon A, et al. Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat. Commun. 2020;11:4682. doi: 10.1038/s41467-020-18463-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18463-z</ArticleId><ArticleId IdType="pmc">PMC7499305</ArticleId><ArticleId IdType="pubmed">32943628</ArticleId></ArticleIdList></Reference><Reference><Citation>Perales C, et al. The increasing impact of lethal mutagenesis of viruses. Future Med. Chem. 2019;11:1645&#x2013;1657. doi: 10.4155/fmc-2018-0457.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2018-0457</ArticleId><ArticleId IdType="pubmed">31469331</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta Y, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antivir. Res. 2009;82:95&#x2013;102. doi: 10.1016/j.antiviral.2009.02.198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.02.198</ArticleId><ArticleId IdType="pmc">PMC7127082</ArticleId><ArticleId IdType="pubmed">19428599</ArticleId></ArticleIdList></Reference><Reference><Citation>Naydenova K, et al. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. Proc. Natl Acad. Sci. USA. 2021;118:e2021946118. doi: 10.1073/pnas.2021946118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2021946118</ArticleId><ArticleId IdType="pmc">PMC7896311</ArticleId><ArticleId IdType="pubmed">33526596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaptein SJF, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc. Natl Acad. Sci. USA. 2020;117:26955&#x2013;26965. doi: 10.1073/pnas.2014441117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2014441117</ArticleId><ArticleId IdType="pmc">PMC7604414</ArticleId><ArticleId IdType="pubmed">33037151</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosaeed M, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin. Microbiol. Infect. 2022;28:602&#x2013;608. doi: 10.1016/j.cmi.2021.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8747778</ArticleId><ArticleId IdType="pubmed">35026375</ArticleId></ArticleIdList></Reference><Reference><Citation>Golan Y, et al. Favipiravir in patients with early mild-to-moderate COVID-19: a randomized controlled trial. Clin. Infect. Dis. 2023;76:e10&#x2013;e17. doi: 10.1093/cid/ciac712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac712</ArticleId><ArticleId IdType="pmc">PMC9494366</ArticleId><ArticleId IdType="pubmed">36065065</ArticleId></ArticleIdList></Reference><Reference><Citation>Holubar M, et al. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial. Clin. Infect. Dis. 2022;75:1883&#x2013;1892. doi: 10.1093/cid/ciac312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac312</ArticleId><ArticleId IdType="pmc">PMC9047233</ArticleId><ArticleId IdType="pubmed">35446944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, et al. Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis. 2017;11:e0005389. doi: 10.1371/journal.pntd.0005389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0005389</ArticleId><ArticleId IdType="pmc">PMC5340401</ArticleId><ArticleId IdType="pubmed">28231247</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett RP, et al. Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties. JCI Insight. 2022;7:e153165. doi: 10.1172/jci.insight.153165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.153165</ArticleId><ArticleId IdType="pmc">PMC8765048</ArticleId><ArticleId IdType="pubmed">34807849</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W, et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat. Struct. Mol. Biol. 2021;28:319&#x2013;325. doi: 10.1038/s41594-021-00570-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-021-00570-0</ArticleId><ArticleId IdType="pubmed">33674802</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemar N, Hauser DA, Maser P. 100 years of suramin. Antimicrob. Agents Chemother. 2020;64:e01168-19. doi: 10.1128/AAC.01168-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01168-19</ArticleId><ArticleId IdType="pmc">PMC7038244</ArticleId><ArticleId IdType="pubmed">31844000</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, et al. Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex. Cell. 2020;182:1560&#x2013;1573.e1513. doi: 10.1016/j.cell.2020.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.033</ArticleId><ArticleId IdType="pmc">PMC7386476</ArticleId><ArticleId IdType="pubmed">32783916</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman JA, et al. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase. Nat. Commun. 2021;12:4848. doi: 10.1038/s41467-021-25166-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25166-6</ArticleId><ArticleId IdType="pmc">PMC8358061</ArticleId><ArticleId IdType="pubmed">34381037</ArticleId></ArticleIdList></Reference><Reference><Citation>Squeglia F, Romano M, Ruggiero A, Maga G, Berisio R. Host DDX helicases as possible SARS-CoV-2 proviral factors: a structural overview of their hijacking through multiple viral proteins. Front. Chem. 2020;8:602162. doi: 10.3389/fchem.2020.602162.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2020.602162</ArticleId><ArticleId IdType="pmc">PMC7769135</ArticleId><ArticleId IdType="pubmed">33381492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gege C, Kleymann G. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037. Expert Opin. Ther. Pat. 2022;32:933&#x2013;937. doi: 10.1080/13543776.2022.2113873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2022.2113873</ArticleId><ArticleId IdType="pubmed">35965439</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, et al. Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme. Science. 2021;373:1142&#x2013;1146. doi: 10.1126/science.abi9310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi9310</ArticleId><ArticleId IdType="pmc">PMC9836006</ArticleId><ArticleId IdType="pubmed">34315827</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L, et al. Coupling of N7-methyltransferase and 3&#x2032;&#x2013;5&#x2032; exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading. Cell. 2021;184:3474&#x2013;3485.e3411. doi: 10.1016/j.cell.2021.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8142856</ArticleId><ArticleId IdType="pubmed">34143953</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddock HT, et al. Characterization of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification. Nucleic Acids Res. 2022;50:1484&#x2013;1500. doi: 10.1093/nar/gkab1303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1303</ArticleId><ArticleId IdType="pmc">PMC8860572</ArticleId><ArticleId IdType="pubmed">35037045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferron F, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc. Natl Acad. Sci. USA. 2018;115:E162&#x2013;E171. doi: 10.1073/pnas.1718806115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1718806115</ArticleId><ArticleId IdType="pmc">PMC5777078</ArticleId><ArticleId IdType="pubmed">29279395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nencka R, et al. Coronaviral RNA-methyltransferases: function, structure and inhibition. Nucleic Acids Res. 2022;50:635&#x2013;650. doi: 10.1093/nar/gkab1279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1279</ArticleId><ArticleId IdType="pmc">PMC8789044</ArticleId><ArticleId IdType="pubmed">35018474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed-Belkacem R, et al. Potent Inhibition of SARS-CoV-2 NSP14 N7-methyltransferase by sulfonamide-based bisubstrate analogues. J. Med. Chem. 2022;65:6231&#x2013;6249. doi: 10.1021/acs.jmedchem.2c00120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.2c00120</ArticleId><ArticleId IdType="pubmed">35439007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillon MC, et al. Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight into nuclease specificity and dynamics. Nat. Commun. 2021;12:636. doi: 10.1038/s41467-020-20608-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20608-z</ArticleId><ArticleId IdType="pmc">PMC7840905</ArticleId><ArticleId IdType="pubmed">33504779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, et al. Crystal structure of Nsp15 endoribonuclease NendoU from SARS-CoV-2. Protein Sci. 2020;29:1596&#x2013;1605. doi: 10.1002/pro.3873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.3873</ArticleId><ArticleId IdType="pmc">PMC7264519</ArticleId><ArticleId IdType="pubmed">32304108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, et al. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2. Commun. Biol. 2021;4:193. doi: 10.1038/s42003-021-01735-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01735-9</ArticleId><ArticleId IdType="pmc">PMC7873276</ArticleId><ArticleId IdType="pubmed">33564093</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan T, et al. A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2&#x2019;-O methylation of its first nucleotide. Nat. Commun. 2021;12:3287. doi: 10.1038/s41467-021-23594-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23594-y</ArticleId><ArticleId IdType="pmc">PMC8172916</ArticleId><ArticleId IdType="pubmed">34078893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobileva O, et al. Potent SARS-CoV-2 mRNA Cap methyltransferase inhibitors by bioisosteric replacement of methionine in SAM cosubstrate. ACS Med. Chem. Lett. 2021;12:1102&#x2013;1107. doi: 10.1021/acsmedchemlett.1c00140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.1c00140</ArticleId><ArticleId IdType="pmc">PMC8204913</ArticleId><ArticleId IdType="pubmed">34257831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergant V, et al. Attenuation of SARS-CoV-2 replication and associated inflammation by concomitant targeting of viral and host cap 2&#x2032;-O-ribose methyltransferases. EMBO J. 2022;41:e111608. doi: 10.15252/embj.2022111608.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2022111608</ArticleId><ArticleId IdType="pmc">PMC9350232</ArticleId><ArticleId IdType="pubmed">35833542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lhuissier E, et al. Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice. Oncotarget. 2018;9:20698&#x2013;20708. doi: 10.18632/oncotarget.25062.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.25062</ArticleId><ArticleId IdType="pmc">PMC5945538</ArticleId><ArticleId IdType="pubmed">29755682</ArticleId></ArticleIdList></Reference><Reference><Citation>Cubuk J, et al. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat. Commun. 2021;12:1936. doi: 10.1038/s41467-021-21953-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21953-3</ArticleId><ArticleId IdType="pmc">PMC8007728</ArticleId><ArticleId IdType="pubmed">33782395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, et al. Targeting liquid-liquid phase separation of SARS-CoV-2 nucleocapsid protein promotes innate antiviral immunity by elevating MAVS activity. Nat. Cell Biol. 2021;23:718&#x2013;732. doi: 10.1038/s41556-021-00710-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-021-00710-0</ArticleId><ArticleId IdType="pubmed">34239064</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W, Zheng Y, Zeng X, He B, Cheng W. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduct. Target. Ther. 2022;7:26. doi: 10.1038/s41392-022-00884-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00884-5</ArticleId><ArticleId IdType="pmc">PMC8793099</ArticleId><ArticleId IdType="pubmed">35087058</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu DX, Fung TS, Chong KK, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. Antivir. Res. 2014;109:97&#x2013;109. doi: 10.1016/j.antiviral.2014.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.06.013</ArticleId><ArticleId IdType="pmc">PMC7113789</ArticleId><ArticleId IdType="pubmed">24995382</ArticleId></ArticleIdList></Reference><Reference><Citation>Vora SM, et al. Targeting stem-loop 1 of the SARS-CoV-2 5&#x2019; UTR to suppress viral translation and Nsp1 evasion. Proc. Natl Acad. Sci. USA. 2022;119:e2117198119. doi: 10.1073/pnas.2117198119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2117198119</ArticleId><ArticleId IdType="pmc">PMC8892331</ArticleId><ArticleId IdType="pubmed">35149555</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambike S, et al. Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res. 2022;50:333&#x2013;349. doi: 10.1093/nar/gkab1248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1248</ArticleId><ArticleId IdType="pmc">PMC8754636</ArticleId><ArticleId IdType="pubmed">34928377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YC, et al. A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant. EMBO Mol. Med. 2022;14:e15298. doi: 10.15252/emmm.202115298.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202115298</ArticleId><ArticleId IdType="pmc">PMC8988202</ArticleId><ArticleId IdType="pubmed">35138028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni JA, et al. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 2021;16:630&#x2013;643. doi: 10.1038/s41565-021-00898-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41565-021-00898-0</ArticleId><ArticleId IdType="pubmed">34059811</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Hingrat Q, et al. Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates. AIDS. 2022;36:1055&#x2013;1060. doi: 10.1097/QAD.0000000000003218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003218</ArticleId><ArticleId IdType="pubmed">35262531</ArticleId></ArticleIdList></Reference><Reference><Citation>Millet JK, Jaimes JA, Whittaker GR. Molecular diversity of coronavirus host cell entry receptors. FEMS Microbiol. Rev. 2021;45:fuaa057. doi: 10.1093/femsre/fuaa057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/femsre/fuaa057</ArticleId><ArticleId IdType="pmc">PMC7665467</ArticleId><ArticleId IdType="pubmed">33118022</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444&#x2013;1448. doi: 10.1126/science.abb2762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm. Sin. B. 2021;11:1&#x2013;12. doi: 10.1016/j.apsb.2020.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2020.10.006</ArticleId><ArticleId IdType="pmc">PMC7553008</ArticleId><ArticleId IdType="pubmed">33072500</ArticleId></ArticleIdList></Reference><Reference><Citation>Karoyan P, et al. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection. Commun. Biol. 2021;4:197. doi: 10.1038/s42003-021-01736-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01736-8</ArticleId><ArticleId IdType="pmc">PMC7881012</ArticleId><ArticleId IdType="pubmed">33580154</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil V, et al. Clinical grade ACE2 as a universal agent to block SARS-CoV-2 variants. EMBO Mol. Med. 2022;14:e15230. doi: 10.15252/emmm.202115230.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.202115230</ArticleId><ArticleId IdType="pmc">PMC9350269</ArticleId><ArticleId IdType="pubmed">35781796</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin YH, et al. Inhibition of ACE2-spike interaction by an ACE2 binder suppresses SARS-CoV-2 entry. Angew. Chem. Int. Ed. 2022;61:e202115695. doi: 10.1002/anie.202115695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202115695</ArticleId><ArticleId IdType="pmc">PMC9011661</ArticleId><ArticleId IdType="pubmed">35043545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280.e278. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch J, et al. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J. 2021;40:e107821. doi: 10.15252/embj.2021107821.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021107821</ArticleId><ArticleId IdType="pmc">PMC8365257</ArticleId><ArticleId IdType="pubmed">34159616</ArticleId></ArticleIdList></Reference><Reference><Citation>Jocher G, et al. ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. EMBO Rep. 2022;23:e54305. doi: 10.15252/embr.202154305.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202154305</ArticleId><ArticleId IdType="pmc">PMC9171409</ArticleId><ArticleId IdType="pubmed">35527514</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng YW, et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. Cell Rep. 2020;33:108254. doi: 10.1016/j.celrep.2020.108254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108254</ArticleId><ArticleId IdType="pmc">PMC7510585</ArticleId><ArticleId IdType="pubmed">33007239</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3&#x2013;20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Laporte M, et al. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways. PLoS Pathog. 2021;17:e1009500. doi: 10.1371/journal.ppat.1009500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009500</ArticleId><ArticleId IdType="pmc">PMC8061995</ArticleId><ArticleId IdType="pubmed">33886690</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock TP, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 2021;6:899&#x2013;909. doi: 10.1038/s41564-021-00908-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00908-w</ArticleId><ArticleId IdType="pubmed">33907312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui KPY, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715&#x2013;720. doi: 10.1038/s41586-022-04479-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04479-6</ArticleId><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature. 2022;603:706&#x2013;714. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Meyerholz DK, Bartlett JA, McCray PB., Jr The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19. mBio. 2021;12:e0097021. doi: 10.1128/mBio.00970-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00970-21</ArticleId><ArticleId IdType="pmc">PMC8406266</ArticleId><ArticleId IdType="pubmed">34340553</ArticleId></ArticleIdList></Reference><Reference><Citation>Brevini T, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2023;615:134&#x2013;142. doi: 10.1038/s41586-022-05594-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05594-0</ArticleId><ArticleId IdType="pmc">PMC9977684</ArticleId><ArticleId IdType="pubmed">36470304</ArticleId></ArticleIdList></Reference><Reference><Citation>Samelson AJ, et al. BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. Nat. Cell Biol. 2022;24:24&#x2013;34. doi: 10.1038/s41556-021-00821-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41556-021-00821-8</ArticleId><ArticleId IdType="pmc">PMC8820466</ArticleId><ArticleId IdType="pubmed">35027731</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H, et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature. 2022;609:785&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">35922005</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J, et al. CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma. Signal. Transduct. Target. Ther. 2021;6:347. doi: 10.1038/s41392-021-00760-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00760-8</ArticleId><ArticleId IdType="pmc">PMC8464593</ArticleId><ArticleId IdType="pubmed">34564690</ArticleId></ArticleIdList></Reference><Reference><Citation>White KM, et al. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science. 2021;371:926&#x2013;931. doi: 10.1126/science.abf4058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4058</ArticleId><ArticleId IdType="pmc">PMC7963220</ArticleId><ArticleId IdType="pubmed">33495306</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, et al. Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition. Proc. Natl Acad. Sci. USA. 2021;118:e2113401118. doi: 10.1073/pnas.2113401118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2113401118</ArticleId><ArticleId IdType="pmc">PMC8594528</ArticleId><ArticleId IdType="pubmed">34593624</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga L, et al. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia. Nature. 2021;594:88&#x2013;93. doi: 10.1038/s41586-021-03491-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03491-6</ArticleId><ArticleId IdType="pmc">PMC7611055</ArticleId><ArticleId IdType="pubmed">33827113</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnette KG, et al. Oral Sabizabulin for high-risk, hospitalized adults with Covid-19: interim analysis. NEJM Evid. 2022;1:EVIDoa2200145. doi: 10.1056/EVIDoa2200145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/EVIDoa2200145</ArticleId><ArticleId IdType="pubmed">38319812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian H, et al. Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial. Signal. Transduct. Target. Ther. 2023;8:46. doi: 10.1038/s41392-023-01323-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-023-01323-9</ArticleId><ArticleId IdType="pmc">PMC9885411</ArticleId><ArticleId IdType="pubmed">36717539</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 2020;20:363&#x2013;374. doi: 10.1038/s41577-020-0311-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science. 2022;375:1122&#x2013;1127. doi: 10.1126/science.abm8108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm8108</ArticleId><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.</Citation><ArticleIdList><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk FL, et al. A guide to immunotherapy for COVID-19. Nat. Med. 2022;28:39&#x2013;50. doi: 10.1038/s41591-021-01643-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01643-9</ArticleId><ArticleId IdType="pubmed">35064248</ArticleId></ArticleIdList></Reference><Reference><Citation>Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 2017;17:233&#x2013;247. doi: 10.1038/nri.2017.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.1</ArticleId><ArticleId IdType="pmc">PMC9761406</ArticleId><ArticleId IdType="pubmed">28192415</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat. Rev. Rheumatol. 2020;16:133&#x2013;144. doi: 10.1038/s41584-020-0371-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0371-y</ArticleId><ArticleId IdType="pubmed">32034322</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, et al. Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19. Nat. Med. 2022;28:201&#x2013;211. doi: 10.1038/s41591-021-01576-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01576-3</ArticleId><ArticleId IdType="pmc">PMC8799469</ArticleId><ArticleId IdType="pubmed">34782790</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Miyazaki K, Shah P, Kozai L, Kewcharoen J. Association between mineralocorticoid receptor antagonist and mortality in SARS-CoV-2 patients: a systematic review and meta-analysis. Healthcare. 2022;10:645. doi: 10.3390/healthcare10040645.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10040645</ArticleId><ArticleId IdType="pmc">PMC9027687</ArticleId><ArticleId IdType="pubmed">35455823</ArticleId></ArticleIdList></Reference><Reference><Citation>The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Alunno A, et al. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Ann. Rheum. Dis. 2022;81:34&#x2013;40. doi: 10.1136/annrheumdis-2021-221366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221366</ArticleId><ArticleId IdType="pubmed">34620584</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe CR, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir. Med. 2022;10:888&#x2013;899. doi: 10.1016/S2213-2600(22)00088-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00088-1</ArticleId><ArticleId IdType="pmc">PMC9126560</ArticleId><ArticleId IdType="pubmed">35617986</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu LM, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398:843&#x2013;855. doi: 10.1016/S0140-6736(21)01744-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01744-X</ArticleId><ArticleId IdType="pmc">PMC8354567</ArticleId><ArticleId IdType="pubmed">34388395</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan S, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir. Med. 2021;9:763&#x2013;772. doi: 10.1016/S2213-2600(21)00160-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00160-0</ArticleId><ArticleId IdType="pmc">PMC8040526</ArticleId><ArticleId IdType="pubmed">33844996</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemency BM, et al. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA Intern. Med. 2022;182:42&#x2013;49. doi: 10.1001/jamainternmed.2021.6759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.6759</ArticleId><ArticleId IdType="pmc">PMC8609464</ArticleId><ArticleId IdType="pubmed">34807241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezer N, et al. Inhaled and intranasal ciclesonide for the treatment of Covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. BMJ. 2021;375:e068060. doi: 10.1136/bmj-2021-068060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068060</ArticleId><ArticleId IdType="pmc">PMC8561042</ArticleId><ArticleId IdType="pubmed">34728476</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin. Immunol. 2013;9:30. doi: 10.1186/1710-1492-9-30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1710-1492-9-30</ArticleId><ArticleId IdType="pmc">PMC3765115</ArticleId><ArticleId IdType="pubmed">23947590</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. Lancet Respir. Med. 2020;8:1170&#x2013;1172. doi: 10.1016/S2213-2600(20)30503-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30503-8</ArticleId><ArticleId IdType="pmc">PMC7598750</ArticleId><ArticleId IdType="pubmed">33129421</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips RL, et al. The JAK&#x2013;STAT pathway at 30: much learned, much more to do. Cell. 2022;185:3857&#x2013;3876. doi: 10.1016/j.cell.2022.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.09.023</ArticleId><ArticleId IdType="pmc">PMC9815833</ArticleId><ArticleId IdType="pubmed">36240739</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbing J, et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci. Adv. 2021;7:eabe4724. doi: 10.1126/sciadv.abe4724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe4724</ArticleId><ArticleId IdType="pmc">PMC7775747</ArticleId><ArticleId IdType="pubmed">33187978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte V, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J. Clin. Invest. 2020;130:6409&#x2013;6416. doi: 10.1172/JCI141772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141772</ArticleId><ArticleId IdType="pmc">PMC8016181</ArticleId><ArticleId IdType="pubmed">32809969</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359&#x2013;368. doi: 10.1016/S0140-6736(22)01109-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01109-6</ArticleId><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi VC, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021;9:1407&#x2013;1418. doi: 10.1016/S2213-2600(21)00331-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 2021;384:795&#x2013;807. doi: 10.1056/NEJMoa2031994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes PO, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 2021;385:406&#x2013;415. doi: 10.1056/NEJMoa2101643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101643</ArticleId><ArticleId IdType="pmc">PMC8220898</ArticleId><ArticleId IdType="pubmed">34133856</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B, et al. SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation. Sci. Immunol. 2021;6:eabg0833. doi: 10.1126/sciimmunol.abg0833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg0833</ArticleId><ArticleId IdType="pmc">PMC8139422</ArticleId><ArticleId IdType="pubmed">33827897</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 2020;8:1233&#x2013;1244. doi: 10.1016/S2213-2600(20)30404-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30404-5</ArticleId><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637&#x2013;1645. doi: 10.1016/S0140-6736(21)00676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas IO, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 2021;384:1503&#x2013;1516. doi: 10.1056/NEJMoa2028700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028700</ArticleId><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 2021;384:1491&#x2013;1502. doi: 10.1056/NEJMoa2100433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2100433</ArticleId><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the REMAP-CAP Investigators. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2022;329:39&#x2013;51. doi: 10.1001/jama.2022.23257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.23257</ArticleId><ArticleId IdType="pmc">PMC9857594</ArticleId><ArticleId IdType="pubmed">36525245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonze BE, et al. A randomized double-blinded placebo controlled trial of clazakizumab for the treatment of COVID-19 pneumonia with hyperinflammation. Crit. Care Med. 2022;50:1348&#x2013;1359. doi: 10.1097/CCM.0000000000005591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000005591</ArticleId><ArticleId IdType="pmc">PMC9380150</ArticleId><ArticleId IdType="pubmed">35583232</ArticleId></ArticleIdList></Reference><Reference><Citation>Temesgen Z, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir. Med. 2022;10:237&#x2013;246. doi: 10.1016/S2213-2600(21)00494-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00494-X</ArticleId><ArticleId IdType="pmc">PMC8635458</ArticleId><ArticleId IdType="pubmed">34863332</ArticleId></ArticleIdList></Reference><Reference><Citation>Criner GJ, et al. Anti-granulocyte-macrophage colony-stimulating factor monoclonal antibody gimsilumab for COVID-19 pneumonia: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2022;205:1290&#x2013;1299. doi: 10.1164/rccm.202108-1859OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202108-1859OC</ArticleId><ArticleId IdType="pmc">PMC9873114</ArticleId><ArticleId IdType="pubmed">35290169</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher BA, et al. Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. Lancet Respir. Med. 2022;10:255&#x2013;266. doi: 10.1016/S2213-2600(21)00460-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00460-4</ArticleId><ArticleId IdType="pmc">PMC8676420</ArticleId><ArticleId IdType="pubmed">34922649</ArticleId></ArticleIdList></Reference><Reference><Citation>Caricchio R, et al. Effect of canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA. 2021;326:230&#x2013;239. doi: 10.1001/jama.2021.9508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.9508</ArticleId><ArticleId IdType="pmc">PMC8293025</ArticleId><ArticleId IdType="pubmed">34283183</ArticleId></ArticleIdList></Reference><Reference><Citation>Resende GG, et al. Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients - the BISHOP study. Infect. Dis. 2022;54:591&#x2013;599. doi: 10.1080/23744235.2022.2066171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2022.2066171</ArticleId><ArticleId IdType="pubmed">35485381</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020;26:1636&#x2013;1643. doi: 10.1038/s41591-020-1051-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1051-9</ArticleId><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>McNab F, Mayer-Barber K, Sher A, Wack A, O&#x2019;Garra A. Type I interferons in infectious disease. Nat. Rev. Immunol. 2015;15:87&#x2013;103. doi: 10.1038/nri3787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3787</ArticleId><ArticleId IdType="pmc">PMC7162685</ArticleId><ArticleId IdType="pubmed">25614319</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoagland DA, et al. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity. 2021;54:557&#x2013;570.e555. doi: 10.1016/j.immuni.2021.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.01.017</ArticleId><ArticleId IdType="pmc">PMC7846242</ArticleId><ArticleId IdType="pubmed">33577760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam AR, et al. Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon beta-1b and remdesivir: a phase 2 open-label randomized controlled trial. Clin. Infect. Dis. 2023;76:e216&#x2013;e226. doi: 10.1093/cid/ciac523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac523</ArticleId><ArticleId IdType="pmc">PMC9278225</ArticleId><ArticleId IdType="pubmed">35762834</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G, et al. Early treatment with pegylated interferon lambda for Covid-19. N. Engl. J. Med. 2023;388:518&#x2013;528. doi: 10.1056/NEJMoa2209760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2209760</ArticleId><ArticleId IdType="pmc">PMC9933926</ArticleId><ArticleId IdType="pubmed">36780676</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N. Engl. J. Med. 2021;384:497&#x2013;511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2021;9:1365&#x2013;1376. doi: 10.1016/S2213-2600(21)00384-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00384-2</ArticleId><ArticleId IdType="pmc">PMC8523116</ArticleId><ArticleId IdType="pubmed">34672949</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico N, Cortinovis M, Suter F, Remuzzi G. Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents. Lancet Infect. Dis. 2023;23:e22&#x2013;e33. doi: 10.1016/S1473-3099(22)00433-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00433-9</ArticleId><ArticleId IdType="pmc">PMC9411261</ArticleId><ArticleId IdType="pubmed">36030796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho JSY, et al. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell. 2021;184:2618&#x2013;2632.e2617. doi: 10.1016/j.cell.2021.03.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.051</ArticleId><ArticleId IdType="pmc">PMC8008343</ArticleId><ArticleId IdType="pubmed">33836156</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvelli J, et al. Association of COVID-19 inflammation with activation of the C5a&#x2013;C5aR1 axis. Nature. 2020;588:146&#x2013;150. doi: 10.1038/s41586-020-2600-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2600-6</ArticleId><ArticleId IdType="pmc">PMC7116884</ArticleId><ArticleId IdType="pubmed">32726800</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaar APJ, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2022;10:1137&#x2013;1146. doi: 10.1016/S2213-2600(22)00297-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00297-1</ArticleId><ArticleId IdType="pmc">PMC9451499</ArticleId><ArticleId IdType="pubmed">36087611</ArticleId></ArticleIdList></Reference><Reference><Citation>Malas MB, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. eClinicalMedicine. 2020;29:100639. doi: 10.1016/j.eclinm.2020.100639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100639</ArticleId><ArticleId IdType="pmc">PMC7679115</ArticleId><ArticleId IdType="pubmed">33251499</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkouh ME, et al. Anticoagulation in patients with COVID-19: JACC review topic of the week. J. Am. Coll. Cardiol. 2022;79:917&#x2013;928. doi: 10.1016/j.jacc.2021.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2021.12.023</ArticleId><ArticleId IdType="pmc">PMC8884342</ArticleId><ArticleId IdType="pubmed">35241226</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N. Engl. J. Med. 2021;385:790&#x2013;802. doi: 10.1056/NEJMoa2105911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399:50&#x2013;59. doi: 10.1016/S0140-6736(21)02392-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02392-8</ArticleId><ArticleId IdType="pmc">PMC8673881</ArticleId><ArticleId IdType="pubmed">34921756</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors JM, et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021;326:1703&#x2013;1712. doi: 10.1001/jama.2021.17272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.17272</ArticleId><ArticleId IdType="pmc">PMC8506296</ArticleId><ArticleId IdType="pubmed">34633405</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco S, et al. Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet Haematol. 2022;9:e585&#x2013;e593. doi: 10.1016/S2352-3026(22)00175-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(22)00175-2</ArticleId><ArticleId IdType="pmc">PMC9243568</ArticleId><ArticleId IdType="pubmed">35779558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ananworanich J, et al. Randomized study of rivaroxaban vs placebo on disease progression and symptoms resolution in high-risk adults with mild coronavirus disease 2019. Clin. Infect. Dis. 2022;75:e473&#x2013;e481. doi: 10.1093/cid/ciab813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab813</ArticleId><ArticleId IdType="pmc">PMC8522357</ArticleId><ArticleId IdType="pubmed">34523673</ArticleId></ArticleIdList></Reference><Reference><Citation>INSPIRATION Investigators. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325:1620&#x2013;1630. doi: 10.1001/jama.2021.4152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.4152</ArticleId><ArticleId IdType="pmc">PMC7974835</ArticleId><ArticleId IdType="pubmed">33734299</ArticleId></ArticleIdList></Reference><Reference><Citation>Moores LK, et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest. 2022;162:213&#x2013;225. doi: 10.1016/j.chest.2022.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2022.02.006</ArticleId><ArticleId IdType="pmc">PMC8839802</ArticleId><ArticleId IdType="pubmed">35167861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuker A, et al. American society of hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5:872&#x2013;888. doi: 10.1182/bloodadvances.2020003763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2020003763</ArticleId><ArticleId IdType="pmc">PMC7869684</ArticleId><ArticleId IdType="pubmed">33560401</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra A, Chakraborty U, Ghosh S, Dasgupta S. Anticoagulation in COVID-19: current concepts and controversies. Postgrad. Med. J. 2022;98:395&#x2013;402. doi: 10.1136/postgradmedj-2021-139923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2021-139923</ArticleId><ArticleId IdType="pubmed">33850011</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, et al. Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: a systematic review and meta-analysis. eClinicalMedicine. 2022;46:101373. doi: 10.1016/j.eclinm.2022.101373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101373</ArticleId><ArticleId IdType="pmc">PMC8989274</ArticleId><ArticleId IdType="pubmed">35434582</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone A, et al. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study. Clin. Infect. Dis. 2022;75:e403&#x2013;e409. doi: 10.1093/cid/ciac014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac014</ArticleId><ArticleId IdType="pmc">PMC8807307</ArticleId><ArticleId IdType="pubmed">35084022</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi G, et al. Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. J. Clin. Invest. 2022;132:e160766. doi: 10.1172/JCI160766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI160766</ArticleId><ArticleId IdType="pmc">PMC9753997</ArticleId><ArticleId IdType="pubmed">36264642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan JI, et al. Remdesivir resistance in transplant recipients with persistent COVID-19. Clin. Infect. Dis. 2023;76:342&#x2013;345. doi: 10.1093/cid/ciac769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac769</ArticleId><ArticleId IdType="pmc">PMC9619446</ArticleId><ArticleId IdType="pubmed">36156117</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyer A, et al. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep. Med. 2022;3:100735. doi: 10.1016/j.xcrm.2022.100735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100735</ArticleId><ArticleId IdType="pmc">PMC9378267</ArticleId><ArticleId IdType="pubmed">36075217</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, De Clercq E. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antivir. Res. 2017;142:83&#x2013;122. doi: 10.1016/j.antiviral.2017.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.02.014</ArticleId><ArticleId IdType="pmc">PMC7172984</ArticleId><ArticleId IdType="pubmed">28238877</ArticleId></ArticleIdList></Reference><Reference><Citation>Pushpakom S, et al. Drug repurposing: progress, challenges &#x2032;and recommendations. Nat. Rev. Drug Discov. 2019;18:41&#x2013;58. doi: 10.1038/nrd.2018.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2018.168</ArticleId><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinthapatla R, et al. Interfering with nucleotide excision by the coronavirus 3&#x2032;-to-5&#x2032; exoribonuclease. Nucleic Acids Res. 2023;51:315&#x2013;336. doi: 10.1093/nar/gkac1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac1177</ArticleId><ArticleId IdType="pmc">PMC9841423</ArticleId><ArticleId IdType="pubmed">36546762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gohl M, et al. From repurposing to redesign: optimization of boceprevir to highly potent inhibitors of the SARS-CoV-2 main protease. Molecules. 2022;27:4292. doi: 10.3390/molecules27134292.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27134292</ArticleId><ArticleId IdType="pmc">PMC9268446</ArticleId><ArticleId IdType="pubmed">35807537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tummino TA, et al. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. 2021;373:541&#x2013;547. doi: 10.1126/science.abi4708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abi4708</ArticleId><ArticleId IdType="pmc">PMC8501941</ArticleId><ArticleId IdType="pubmed">34326236</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley CG, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci. Transl. Med. 2021;13:eabd5524. doi: 10.1126/scitranslmed.abd5524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd5524</ArticleId><ArticleId IdType="pubmed">34550729</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaki MM, et al. Cell therapy strategies for COVID-19: current approaches and potential applications. Sci. Adv. 2021;7:eabg5995. doi: 10.1126/sciadv.abg5995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abg5995</ArticleId><ArticleId IdType="pmc">PMC8357240</ArticleId><ArticleId IdType="pubmed">34380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AJ, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 2019;169:104541. doi: 10.1016/j.antiviral.2019.104541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104541</ArticleId><ArticleId IdType="pmc">PMC6699884</ArticleId><ArticleId IdType="pubmed">31233808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, et al. 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors. Antivir. Res. 2021;196:105209. doi: 10.1016/j.antiviral.2021.105209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2021.105209</ArticleId><ArticleId IdType="pmc">PMC8600920</ArticleId><ArticleId IdType="pubmed">34801588</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurard-Levin ZA, et al. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry. Antivir. Res. 2020;182:104924. doi: 10.1016/j.antiviral.2020.104924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104924</ArticleId><ArticleId IdType="pmc">PMC7834858</ArticleId><ArticleId IdType="pubmed">32896566</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, et al. Drug discovery of nucleos(t)ide antiviral agents: dedicated to Prof. Dr. Erik De Clercq on occasion of his 80th birthday. Molecules. 2021;26:923. doi: 10.3390/molecules26040923.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26040923</ArticleId><ArticleId IdType="pmc">PMC7916218</ArticleId><ArticleId IdType="pubmed">33572409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewley KR, et al. Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat. Protoc. 2021;16:3114&#x2013;3140. doi: 10.1038/s41596-021-00536-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-021-00536-y</ArticleId><ArticleId IdType="pubmed">33893470</ArticleId></ArticleIdList></Reference><Reference><Citation>Bestion E, Halfon P, Mezouar S, Mege JL. Cell and animal models for SARS-CoV-2 research. Viruses. 2022;14:1507. doi: 10.3390/v14071507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071507</ArticleId><ArticleId IdType="pmc">PMC9319816</ArticleId><ArticleId IdType="pubmed">35891487</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers MM, et al. An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. EMBO J. 2021;40:e105912. doi: 10.15252/embj.2020105912.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020105912</ArticleId><ArticleId IdType="pmc">PMC7883112</ArticleId><ArticleId IdType="pubmed">33283287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukowy-Bieryllo Z. Long-term differentiating primary human airway epithelial cell cultures: how far are we. Cell Commun. Signal. 2021;19:63. doi: 10.1186/s12964-021-00740-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-021-00740-z</ArticleId><ArticleId IdType="pmc">PMC8159066</ArticleId><ArticleId IdType="pubmed">34044844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez S, et al. Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication. Antimicrob. Agents Chemother. 2021;65:e0009721. doi: 10.1128/AAC.00097-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00097-21</ArticleId><ArticleId IdType="pmc">PMC8406809</ArticleId><ArticleId IdType="pubmed">33903110</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269&#x2013;271. doi: 10.1038/s41422-020-0282-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId><ArticleId IdType="pmc">PMC7054408</ArticleId><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, et al. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020;585:588&#x2013;590. doi: 10.1038/s41586-020-2575-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2575-3</ArticleId><ArticleId IdType="pubmed">32698190</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JJH, et al. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob. Health. 2021;9:e711&#x2013;e720. doi: 10.1016/S2214-109X(20)30542-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(20)30542-8</ArticleId><ArticleId IdType="pmc">PMC8049590</ArticleId><ArticleId IdType="pubmed">33865476</ArticleId></ArticleIdList></Reference><Reference><Citation>Esper FP, et al. Alpha to omicron: disease severity and clinical outcomes of major SARS-CoV-2 variants. J. Infect. Dis. 2023;227:344&#x2013;352. doi: 10.1093/infdis/jiac411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac411</ArticleId><ArticleId IdType="pmc">PMC9619650</ArticleId><ArticleId IdType="pubmed">36214810</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JJH, Detry MA, Murthy S, Guyatt G, Mills EJ. How to use and interpret the results of a platform trial: users&#x2019; guide to the medical literature. JAMA. 2022;327:67&#x2013;74. doi: 10.1001/jama.2021.22507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.22507</ArticleId><ArticleId IdType="pubmed">34982138</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikkinen KAO, Malekzadeh R, Schlegel M, Rutanen J, Glasziou P. COVID-19 clinical trials: learning from exceptions in the research chaos. Nat. Med. 2020;26:1671&#x2013;1672. doi: 10.1038/s41591-020-1077-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1077-z</ArticleId><ArticleId IdType="pubmed">32963376</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D, et al. Trajectory of long covid symptoms after Covid-19 vaccination: community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. Long-COVID treatments: why the world is still waiting. Nature. 2022;608:258&#x2013;260. doi: 10.1038/d41586-022-02140-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02140-w</ArticleId><ArticleId IdType="pubmed">35945375</ArticleId></ArticleIdList></Reference><Reference><Citation>Park GJ, et al. The mechanism of RNA capping by SARS-CoV-2. Nature. 2022;609:793&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9492545</ArticleId><ArticleId IdType="pubmed">35944563</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Sivan M, Delaney B, Evans R, Milne R. Long covid &#x2014; an update for primary care. BMJ. 2022;378:e072117. doi: 10.1136/bmj-2022-072117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072117</ArticleId><ArticleId IdType="pubmed">36137612</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, &amp; BA.5. Nature. 2022;608:603&#x2013;608. doi: 10.1038/s41586-022-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05053-w</ArticleId><ArticleId IdType="pmc">PMC9385487</ArticleId><ArticleId IdType="pubmed">35790190</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum DC, June CH. Cytokine storm. N. Engl. J. Med. 2020;383:2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie MJ, et al. Of bats and men: immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci. Immunol. 2021;6:eabd0205. doi: 10.1126/sciimmunol.abd0205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd0205</ArticleId><ArticleId IdType="pubmed">34533977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678&#x2013;692. doi: 10.1038/s41422-020-0356-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0356-z</ArticleId><ArticleId IdType="pmc">PMC7294525</ArticleId><ArticleId IdType="pubmed">32541865</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan L, et al. A mechanism for SARS-CoV-2 RNA capping and its inhibition by nucleotide analog inhibitors. Cell. 2022;185:4347&#x2013;4360.e4317. doi: 10.1016/j.cell.2022.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.09.037</ArticleId><ArticleId IdType="pmc">PMC9531661</ArticleId><ArticleId IdType="pubmed">36335936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, et al. Crystal structure of SARS-CoV-2 nsp10 bound to Nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity. Nucleic Acids Res. 2021;49:5382&#x2013;5392. doi: 10.1093/nar/gkab320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab320</ArticleId><ArticleId IdType="pmc">PMC8136770</ArticleId><ArticleId IdType="pubmed">33956156</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer A, et al. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci. Transl. Med. 2022;14:eabm3410. doi: 10.1126/scitranslmed.abm3410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abm3410</ArticleId><ArticleId IdType="pmc">PMC8995034</ArticleId><ArticleId IdType="pubmed">35315683</ArticleId></ArticleIdList></Reference><Reference><Citation>Tempestilli M, et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J. Antimicrob. Chemother. 2020;75:2977&#x2013;2980. doi: 10.1093/jac/dkaa239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa239</ArticleId><ArticleId IdType="pmc">PMC7337789</ArticleId><ArticleId IdType="pubmed">32607555</ArticleId></ArticleIdList></Reference><Reference><Citation>Cevik M, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021;2:e13&#x2013;e22. doi: 10.1016/S2666-5247(20)30172-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30172-5</ArticleId><ArticleId IdType="pmc">PMC7837230</ArticleId><ArticleId IdType="pubmed">33521734</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkhipova-Jenkins I, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann. Intern. Med. 2021;174:811&#x2013;821. doi: 10.7326/M20-7547.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-7547</ArticleId><ArticleId IdType="pmc">PMC8025942</ArticleId><ArticleId IdType="pubmed">33721517</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM, Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452&#x2013;461. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>